Received May 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
diagnosed with fibromyalgia after receiving Shingrix; This non-serious case was reported by a consumer via call center representative and described the occurrence of fibromyalgia in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced fibromyalgia (Verbatim: diagnosed with fibromyalgia after receiving Shingrix). The outcome of the fibromyalgia was not resolved. It was unknown if the reporter considered the fibromyalgia to be related to Shingrix. It was unknown if the company considered the fibromyalgia to be related to Shingrix. Additional Information: GSK receipt date: 29-APR-2025 The patient reported that after receiving Shingrix vaccine she diagnosed with fibromyalgia. The patient reported fibromyalgia was reported as worsened. The batch/lot number of Shingrix were unknown at the time of reporting.